Pioneering new therapies for cancer

LATEST NEWS

First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in AML
Press Release


First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in MDS
Press Release


Correlation between Gene Mutations and Clinical Response in Phase 2 Study of Pracinostat and Azacitidine in AML
Press Release | ASCO | EHA


Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in CLL and Follicular Lymphoma
Press Release


Third Quarter Fiscal Year 2017 Results
Press Release | 10-Q


Presentation at Needham Healthcare Conference
Webcast | Slides